ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016
Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03121235 (PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome. A Prospective Multicenter Observational Study.), which is not on this map. Cited by 305 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome. A Prospective Multicenter Observational Study.
Who cites it
305 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Healthcare Utilization and Impact of Antifungal Stewardships Within Respiratory Care Settings: A Systematic Literature Review.Mycopathologia · 2021Pooled it
- A systematic review of the impact of antifungal stewardship interventions in the United States.Annals of clinical microbiology and antimicrobials · 2019Pooled it
- Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial.Intensive care medicine · 2021Trial
- First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults.Antimicrobial agents and chemotherapy · 2019Trial
- A long noncoding RNA regulates in vitro and in vivo triazole antifungal susceptibility in Aspergillus fumigatus.Genetics · 2026Article
- Diagnostic Failure in Invasive Fungal Infections: Causes, Clinical Consequences, and Mitigation Strategies.Journal of fungi (Basel, Switzerland) · 2026Review
- Article
- In vitro evaluation of Curcuma longa extract for antifungal, antibiofilm, and synergistic activity against Candida spp.Scientific reports · 2026Article
- Article
- Expression Profiling and Molecular Modeling Analysis ofJournal of fungi (Basel, Switzerland) · 2026Article
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- Azole Resistance inOpen forum infectious diseases · 2026Article
- Novel cyp51A mutation profile in Aspergillus fumigatus from a patient with systemic lupus erythematosus and limited systemic sclerosis: first clinical case of acquired azole-resistance in Colombia.BMC infectious diseases · 2026Article
- Fungal-Associated Endotypes as a Treatable Trait in Bronchiectasis.Pulmonary therapy · 2026Review
- The chromatin remodeling factor Arp9 modulates drug-resistance and plays a key role in aflatoxins biosynthesis under mammalian-physiological-temperature in Aspergillus flavus.PLoS pathogens · 2026Article
- BeyondAntimicrobial agents and chemotherapy · 2026Article
- Regulated proteolysis of green fluorescent protein fusion proteins in Aspergillus fumigatus.G3 (Bethesda, Md.) · 2026Article
- Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026Review
- Novel Genetic Diversity and Geographic Structures ofMicroorganisms · 2026Article
245 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Azole resistance in Aspergillus fumigatus has emerged as a global health problem. Although the number of cases of azole-resistant aspergillosis is still limited, resistance mechanisms continue to emerge, thereby threatening the role of the azole class in the management of diseases caused by Aspergillus. The majority of cases of azole-resistant disease are due to resistant A. fumigatus originating from the environment. Patient management is difficult due to the absence of patient risk factors, delayed diagnosis, and limited treatment options, resulting in poor treatment outcome. International and collaborative efforts are required to understand how resistance develops in the environment to allow effective measures to be implemented aimed at retaining the use of azoles both for food production and human medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.